Gene editing based therapeutics have tremendous clinical potential and are currently being investigated for a variety of indications. However, several challenges need to be solved before the clinical potential of gene editing can be realized. In this presentation, Professor Niren Murthy (UC Berkeley) and Dr. Kunwoo Lee (CEO of GenEdit) will discuss the history of gene editing and present an overview of exciting recent developments in the field. Clinical stage ex vivo approaches targeting disorders like sickle cell disease, cancer, and HIV, and in vivo approaches targeting monogenic disorders in various tissues will be discussed. In addition, they will present recent work of their own, which is focused on solving the delivery challenges associated with in vivo gene editing. Following the presentation, Dr. Derek Sloan from GenEdit will moderate an audience Q&A session.